BLACK DIAMOND THERAPEUTICS, INC.

Analyst Reco. Black Diamond Therapeutics, Inc. OTC Markets

Equities

BDTX

US09203E1055

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-.--%

06-01	Black Diamond Therapeutics, Inc. Presents Promising Bdtx-1535 Clinical Data in Patients with Recurrent Glioblastoma At 2024 American Society of Clinical Oncology Annual Meeting	CI
05-16	HC Wainwright Adjusts Price Target on Black Diamond Therapeutics to $11 From $12, Keeps Buy Rating	MT

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

HC Wainwright Adjusts Price Target on Black Diamond Therapeutics to $11 From $12, Keeps Buy Rating	05-16	MT
Wedbush Adjusts Price Target on Black Diamond Therapeutics to $16 From $10 After Market Confirmation for Drug, Maintains Outperform Rating	04-08	MT
Piper Sandler Initiates Black Diamond Therapeutics With Overweight Rating, $11 Price Target	14/07/23	MT
Stifel Upgrades Black Diamond Therapeutics to Buy From Hold, Adjusts Price Target to $10 From $2	30/06/23	MT
HC Wainwright Upgrades Black Diamond Therapeutics to Buy From Neutral, Price Target is $11	28/06/23	MT
Wedbush Upgrades Black Diamond Therapeutics to Outperform From Neutral, Adjusts Price Target to $10 From $3	27/06/23	MT
Wedbush Lowers Price Target for Black Diamond Therapeutics to $3 From $4, Maintains Neutral Rating	12/05/22	MT
Berenberg Bank Adjusts Black Diamond Therapeutics Price Target to $16 From $34, Maintains Buy Rating	01/04/22	MT
Wedbush Downgrades Black Diamond Therapeutics to Neutral From Outperform, Citing BDTX-1535 Timeline, Likely BDTX-189 Discontinuation, 'Tough' Financing Environment; PT to $4 From $22	29/03/22	MT
HC Wainwright Downgrades Black Diamond Therapeutics to Neutral From Buy	22/03/22	MT
Stifel Adjusts Price Target on Black Diamond Therapeutics to $4 From $10, Reiterates Hold Rating	18/03/22	MT
BLACK DIAMOND THERAPEUTICS : Stifel Starts Black Diamond Therapeutics at Hold With $10 Price Target	30/09/21	MT
BLACK DIAMOND THERAPEUTICS : Wedbush Lowers PT for Black Diamond Therapeutics to $22 From $48 Following BDTX-189 Data, Reiterates Outperform Rating	17/08/21	MT
BLACK DIAMOND THERAPEUTICS : Berenberg Bank Adjusts Black Diamond Therapeutics PT to $34 From $58, Maintains Buy Rating	17/08/21	MT
BLACK DIAMOND THERAPEUTICS : Wedbush Removes Outperform-Rated Black Diamond Therapeutics From Best Ideas List; Price Target is $48	21/05/21	MT
BLACK DIAMOND THERAPEUTICS : Wedbush Adds Outperform-Rated Black Diamond Therapeutics to Best Ideas List; Price Target is $48	29/03/21	MT
BLACK DIAMOND THERAPEUTICS : Wedbush Adjusts Price Target on Black Diamond Therapeutics to $48 From $45, Keeps Outperform Rating	26/03/21	MT
BLACK DIAMOND THERAPEUTICS : Wedbush Starts Black Diamond Therapeutics at Outperform With $45 Price Target	07/01/21	MT
BLACK DIAMOND THERAPEUTICS : Berenberg Starts Black Diamond Therapeutics at Buy With $58 Price Target	24/11/20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Rankings

More Top / Flop

Rankings

More Top / Flop

Currency / Forex

Commodities

Cryptocurrencies

Cryptocurrencies

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW